Treatment on U87MG glioma cell lines and patient-derived primary S1 glioblastoma cells have seen ATO suppression of miR182-5p subsequently increasing Argonate-2 (AGO2)-gene silencing of Sestrin 2 (SESN2 protein coding gene) [132]. This evidence concerns the gene SESN2 and central nervous system cancer.